ACRS

ACLARIS THERAPEUTICS INC

ACRS·00461U105·US·Common Stock·Healthcare - Biotechnology-13D/G

ACRS (ACLARIS THERAPEUTICS INC) is held by 87 institutional investors as of Q2 2026. Largest holders: RA CAPITAL MANAGEMENT, L.P. ($67.3M), BlackRock, Inc. ($53.1M), VANGUARD CAPITAL MANAGEMENT LLC ($30.8M). Net institutional sentiment: Bullish.

87
Holders
(7 Elite)
$321.8M
Total Value
67% (91)
Consensus
61 buying - 30 selling
13F: Insider & Congress: Updated regularly
ACRS

Smart Money Verdict

View all
Loading verdict
Held by 87 funds
7 elite

Who's Trading

Source dates: Price Oct 16, 2026 · Insiders Aug 4, 2026 · Activists Sep 21, 2026 · Congress none

ActivistFLFrazier Life Sciences Public Fund, L.P.5.4%Sep 21, 2026
ActivistRA Capital Management, L.P.RA Capital Management, L.P.9.1%Aug 14, 2026
InsiderKWKolbeck Roland WilhelmTax 12K shAug 1, 2026
Checking access…

Top Holders

Checking access…
Action
Increased
12.7M(+87.0%)$67.3M0.6%-26.56%
65
Increased
10M(+35.5%)$53.1M0.0%+20.32%
38
Increased
5.8M(+12.6%)$30.8M0.0%-16.37%
32
Increased
4.1M(+5.2%)$21.5M0.0%+18.24%
30
Increased
3.3M(+62.1%)$17.2M0.0%-24.02%
41
Increased
3.2M(+31.6%)$16.9M0.0%-27.11%
36
Decreased
2M(-39.8%)$10.7M0.0%-12.53%
0
Decreased
1.8M(-21.7%)$9.3M0.0%+20.17%
0
Increased
1.6M(+8.4%)$8.5M0.0%-7.06%
30
Decreased
1.5M(-11.5%)$7.8M0.0%-12.53%
0
Increased
1.4M(+170.0%)$7.2M0.0%-29.39%
44
Decreased
1.2M(-14.7%)$6.4M0.0%+46.38%
0
Increased
1M(+4.3%)$5.5M0.0%-7.98%
28
Increased
998,763(+37.1%)$5.3M0.0%-20.89%
35
Increased
907,173(+44.3%)$4.8M0.0%-22.32%
36
Increased
817,531(+62.6%)$4.3M0.0%+12.53%
39
Increased
609,158(+3.5%)$3.2M0.0%+60.89%
27
Decreased
523,895(-30.7%)$2.8M0.0%+1.04%
0
Increased
513,840(+0.5%)$2.7M0.0%-6.41%
26
Decreased
468,964(-3.6%)$2.4M0.0%+96.01%
0

Showing 1-20 of 96

1 / 5
ACRSACRSACLARIS THERAPEUTICS INC

Other Healthcare stocks held by institutions

Data sourced from four public-disclosure sources: SEC 13F, Form 4, 13D/13G, and House/Senate STOCK Act disclosures. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used